MX2024004558A - Tratamiento de la uveitis con inhibidores de la aminopeptidasa 1 de reticulo endoplasmatico (erap1). - Google Patents

Tratamiento de la uveitis con inhibidores de la aminopeptidasa 1 de reticulo endoplasmatico (erap1).

Info

Publication number
MX2024004558A
MX2024004558A MX2024004558A MX2024004558A MX2024004558A MX 2024004558 A MX2024004558 A MX 2024004558A MX 2024004558 A MX2024004558 A MX 2024004558A MX 2024004558 A MX2024004558 A MX 2024004558A MX 2024004558 A MX2024004558 A MX 2024004558A
Authority
MX
Mexico
Prior art keywords
uveitis
erap1
inhibitors
treatment
endoplasmic reticulum
Prior art date
Application number
MX2024004558A
Other languages
English (en)
Spanish (es)
Inventor
Carmelo Romano
Sahar Gelfman
Aris Baras
Giovanni Coppola
Jonathan Weyne
Ann Ligocki
Arden Moscati
Eli A Stahl
Huergo Santiago Mendez
Zyl Tave Van
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2024004558A publication Critical patent/MX2024004558A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Analytical Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024004558A 2021-10-14 2022-10-13 Tratamiento de la uveitis con inhibidores de la aminopeptidasa 1 de reticulo endoplasmatico (erap1). MX2024004558A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163255597P 2021-10-14 2021-10-14
US202263328008P 2022-04-06 2022-04-06
PCT/US2022/078037 WO2023064850A1 (en) 2021-10-14 2022-10-13 Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (erap1) inhibitors

Publications (1)

Publication Number Publication Date
MX2024004558A true MX2024004558A (es) 2024-07-10

Family

ID=84332068

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024004558A MX2024004558A (es) 2021-10-14 2022-10-13 Tratamiento de la uveitis con inhibidores de la aminopeptidasa 1 de reticulo endoplasmatico (erap1).

Country Status (5)

Country Link
US (2) US12157891B2 (cg-RX-API-DMAC7.html)
EP (1) EP4416286A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024536491A (cg-RX-API-DMAC7.html)
MX (1) MX2024004558A (cg-RX-API-DMAC7.html)
WO (1) WO2023064850A1 (cg-RX-API-DMAC7.html)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8968731B2 (en) * 2009-10-09 2015-03-03 Csl Limited Treatment of uveitis
WO2012047294A2 (en) 2010-10-06 2012-04-12 Ludwig Institute For Cancer Research Ltd Antibodies directed against hla-b27 homodimers and methods and uses thereof in diagnosis and therapy
TWI619729B (zh) * 2012-04-02 2018-04-01 再生元醫藥公司 抗-hla-b*27抗體及其用途
WO2014155278A2 (en) * 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
US12377084B2 (en) 2019-11-14 2025-08-05 Grey Wolf Therapeutics Limited ERAP1 modulators
CA3189755A1 (en) 2020-07-25 2022-02-03 Regeneron Pharmaceuticals, Inc. Modulation of endoplasmic reticulum aminopeptidase 2 (erap2)-mediated immune response

Also Published As

Publication number Publication date
US20250115918A1 (en) 2025-04-10
US12157891B2 (en) 2024-12-03
US20230250434A1 (en) 2023-08-10
EP4416286A1 (en) 2024-08-21
JP2024536491A (ja) 2024-10-04
WO2023064850A1 (en) 2023-04-20

Similar Documents

Publication Publication Date Title
MA49508B1 (fr) Procédés de traitement d'une insuffisance cardiaque avec des activateurs de sarcomères cardiaques
JOP20250160A1 (ar) التحلل المستهدف لـ vav1
EA200700333A1 (ru) Терапевтические применения ингибиторов rtp801
EA202191133A1 (ru) Сигнатуры интерферона типа i и способы их применения
CY1109295T1 (el) Μεθοδοι για την αντιμετωπιση της νοσου παρκινσον
BRPI0309665B8 (pt) método para analisar uma preparação de alfagalactosidase a
CY1115745T1 (el) Συνθεσεις και μεθοδοι για αντιμετωπιση ή προληψη σχετιζομενης με οξαλικα νοσου
EP1639141A4 (en) METHOD FOR THE TREATMENT OF LENTIVIRUS INFECTIONS
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
DK1680507T3 (da) Bakterieekspression af proteaseinhibitorer og varianter deraf
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
WO2022015573A3 (en) Sars-cov-2 antigen-binding proteins and uses thereof
BR112022013646A2 (pt) Método de tratamento de esplenomegalia
BR112021017550A2 (pt) Métodos de tratamento da amiloidose al
MX2025005119A (es) Degradantes de nek7 y métodos de uso de estos
MX2022014254A (es) Anticuerpos anti-hemojuvelina (hjv) para tratar mielofibrosis.
MX2023001059A (es) Modulacion de la respuesta inmunitaria mediada por la aminopeptidasa 2 del reticulo endoplasmico (erap2).
EA202192961A1 (ru) Ребамипид для применения в профилактике и/или лечении синуклеинопатий
EA202192176A1 (ru) Нарушения, опосредованные интерфероном i типа
MX2025005212A (es) Tratamiento de enfermedades renales con una combinación de inhibidores de angiopoyetina tipo 3 (angptl3) e inhibidores del miembro 2 de la familia 5 de transportadores de solutos (slc5a2)
MX2020013100A (es) Metodos de uso de cd24 para la prevencion y tratamiento de enfermedad de injerto contra hospedero y mucositis.
EA202190862A1 (ru) Способы лечения
NO20055450L (no) Kombinasjon av et analeptisk modafinili og en antidepressiv forbindelse for behandling av depresjon
NO20055448L (no) Kombinasjon av et analeptisk modafinil og en antidepressiv forbindelse for behandling av depresjon
MX2024007900A (es) Tratamiento de enfermedades renales con inhibidores de la angiopoyetina tipo 3 (angptl3).